About Vanquest Pharma Private Limited
Data last updated:
Vanquest Pharma Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 12 June 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24304MH2019PTC326607. Its GSTIN is 27AAGCV9740D1Z4 (Maharashtra).
The company has an authorised share capital of ₹1 Cr and a paid-up capital of ₹1 Cr. It is led by directors including Pavan H Patel and Hiten Patel.
Its last annual general meeting (AGM) was held on 26 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹39.34 Cr, a decline of 15% compared to the previous year. For the same year it recorded a net loss of ₹29.48 Cr (net margin -74.9%) and EBITDA of -₹11.17 Cr (EBITDA margin -28.4%). Revenue has grown at a compounded annual rate (CAGR) of 542% over three years.
The company has about 134 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Vanquest Pharma. As per MCA filings, the company has open charges of ₹60 Cr and satisfied charges of ₹53.2 Cr on record. The company has 2 deals on record (1 rights issue, 1 secondary share transfer); the latest was in May 2022. Its 10 peer companies in the same principal business activity (Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 5 smaller; the largest is Shruti Drugs Private Limited with revenue of ₹39.47 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website vanquestpharma.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered Address208 Town Centre Comm Prem Coop Soc Ltd, Nr Mahalaxmi Andheri East, Mumbai, Maharashtra, India – 400059
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Vanquest Pharma Private Limited
The main business activity of Vanquest Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Vanquest Pharma Private Limited FY 2025 filings available
Vanquest Pharma Private Limited reported revenue of ₹39.34 Cr (down 15% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Vanquest Pharma Private Limited
Revenue fell 15% in the latest year, but over three years it has grown at a compounded annual rate (CAGR) of 542%. EBITDA fell 11% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Vanquest Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | -₹11.17 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | -₹29.48 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Vanquest Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -28.4% | •••• | •••• | •••• | •••• |
| Net Profit Margin | -74.9% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Vanquest Pharma are in the company report.
Financial statements from FY 2020
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Vanquest Pharma Private Limited
Vanquest Pharma Private Limited is compared with the companies closest to it by revenue in the same principal business activity (Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Shruti Drugs Private Limited | ₹39.47 Cr (FY 2025) | •••• | •••• | 35.0% | •••• | Secunderabad, Telangana, India |
| Acechemie Zynk Energy Limited | ₹39.46 Cr (FY 2024) | •••• | •••• | 3.0% | •••• | Amod, Gujarat, India |
| QB Biotechnology Private Limited | ₹39.42 Cr (FY 2025) | •••• | •••• | 47.0% | •••• | Borivali West, Maharashtra, India |
| Eurosyntec Chemicals Private Limited | ₹39.41 Cr (FY 2025) | •••• | •••• | 6.0% | •••• | Navi Mumbai, Maharashtra, India |
| Rex Remedies Limited | ₹39.37 Cr (FY 2025) | •••• | •••• | -11.0% | •••• | Delhi, India |
| Vanquest Pharma Private Limited this company | ₹39.34 Cr (FY 2025) | •••• | •••• | -15.0% | •••• | Mumbai, Maharashtra, India |
| Carbon Light Private Limited | ₹39.32 Cr (FY 2025) | •••• | •••• | 120.0% | •••• | Ghaziabad, Uttar Pradesh, India |
| Strides Emerging Markets Limited | ₹39.32 Cr (FY 2020) | •••• | •••• | 735.0% | •••• | Bangalore, Karnataka, India |
| Giyaan Pharma Private Limited | ₹39.31 Cr (FY 2024) | •••• | •••• | 16.0% | •••• | Serilingampally, Telangana, India |
| Qipc Eae India Private Limited | ₹39.29 Cr (FY 2024) | •••• | •••• | 46.0% | •••• | Sanand, Gujarat, India |
| Discovery Laboratories Private Limited | ₹39.29 Cr (FY 2025) | •••• | •••• | 99.0% | •••• | Hyderabad, Telangana, India |
Peers are the five companies nearest above and the five nearest below Vanquest Pharma by revenue in the same principal business activity (Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Vanquest Pharma Private Limited
Vanquest Pharma Private Limited is audited by SohanS.Jain& Co. for the financial year 2024.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| SohanS.Jain& Co. | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Vanquest Pharma Private Limited
Vanquest Pharma has 6 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pavan H Patel | Director | 12 Jun 2019 | 7 Years 3 Months | Current |
| Hiten Patel | Director | 12 Jun 2019 | 7 Years 3 Months | Current |
| Manish Babulal Jain Also directs: Medorbis Trade LLP, Naprod Life Sciences Private Limited, Miracalus Pharma Private Limited and 2 more | Director | 12 Jun 2019 | 7 Years 3 Months | Current |
| Mohan Babulal Jain Also directs: Medorbis Trade LLP, Naprod Life Sciences Private Limited, Miracalus Pharma Private Limited and 2 more | Director | 12 Jun 2019 | 7 Years 3 Months | Current |
| Pratik Hitenkumar Patel | Director | 12 Jun 2019 | 7 Years 3 Months | Current |
| Aarya Mohan Jain Also directs: Medorbis Trade LLP, Naprod Life Sciences Private Limited, Miracalus Pharma Private Limited and 1 more | Additional Director | 26 Mar 2025 | 1 Years 6 Months | Current |
Ownership and Shareholding of Vanquest Pharma Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Vanquest Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Mar 2024 | Others | ₹60 Cr | Open |
| 27 Aug 2021 | Others | ₹53.2 Cr | Satisfied |
Total charge records: 2 View all charges
Deals & Funding of Vanquest Pharma Private Limited
Vanquest Pharma Private Limited has 2 deals on record (1 rights issue, 1 secondary share transfer); the latest was in May 2022.
Deals on record (2 of 2)
| When | Deal | Amount | Parties |
|---|---|---|---|
| May 2022 | Rights issue | ₹99 Lakh | Investors: 4 individuals |
| Mar 2022 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
Full deal history
All 2 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Associated Brands with Vanquest Pharma Private Limited
Vanquest Pharma operates one associated brand: Vanquest Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| API manufacturing and regulatory services in the healthcare sector. | vanquestpharma.com |
Employees and EPFO Compliance at Vanquest Pharma Private Limited
Vanquest Pharma Private Limited has a workforce of 134 employees as of Apr 05, 2025.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Vanquest Pharma Private Limited
Vanquest Pharma Private Limited has 8 board changes on record since 2019: 6 appointments and 2 cessations. The latest: Aarya Mohan Jain was appointed as Additional Director on 26 Mar 2025.
4 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Vanquest Pharma Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Vanquest Pharma Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Vanquest Pharma Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Vanquest Pharma Private Limited
Vanquest Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAGCV9740D1Z4 | Maharashtra | Active | 24 Jul 2019 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Vanquest Pharma Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vanquest Pharma Private Limited
Vanquest Pharma is an active private limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 12 June 2019 (7+ years old) and is registered under CIN U24304MH2019PTC326607.
Vanquest Pharma reported revenue of ₹39.34 Cr for FY 2025 (down 15% YoY).
Vanquest Pharma has 6 current directors:
- Pavan H Patel - Director
- Hiten Patel - Director
- Manish Babulal Jain - Director
- Mohan Babulal Jain - Director
- Pratik Hitenkumar Patel - Director
- Aarya Mohan Jain - Additional Director
Vanquest Pharma reported a net loss of ₹29.48 Cr (net margin -74.9%) and EBITDA of -₹11.17 Cr (EBITDA margin -28.4%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Vanquest Pharma is 542% over three years. In the latest year (FY 2025) revenue fell 15%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Vanquest Pharma is 27AAGCV9740D1Z4, registered in Maharashtra.
The CIN (Corporate Identification Number) of Vanquest Pharma is U24304MH2019PTC326607. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Vanquest Pharma was incorporated on 12 June 2019, making it 7+ years old. It is registered with the Registrar of Companies, Mumbai.
Vanquest Pharma has 2 deals on record (1 rights issue, 1 secondary share transfer); the latest was in May 2022.
The peers of Vanquest Pharma by revenue are Shruti Drugs Private Limited, Acechemie Zynk Energy Limited, QB Biotechnology Private Limited, Eurosyntec Chemicals Private Limited, Rex Remedies Limited and 5 more, all in the same principal business activity (Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Aarya Mohan Jain was appointed as Additional Director on 26 Mar 2025. Kamala Babulal Jain ceased to be Director on 25 Mar 2025. Babulal Kesharimal Jain ceased to be Director on 08 Jan 2021. Vanquest Pharma has 8 board changes on record in total.